Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from European Medicines Agency

17:32 EDT 18th June 2018 | BioPortfolio

Here are the most relevant search results for "European Medicines Agency" found in our extensive news archives from over 250 global news sources.

More Information about European Medicines Agency on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about European Medicines Agency for you to read. Along with our medical data and news we also list European Medicines Agency Clinical Trials, which are updated daily. BioPortfolio also has a large database of European Medicines Agency Companies for you to search.

Showing News Articles 1–25 of 4,500+ from European Medicines Agency

Friday 15th June 2018

Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Revision: 4, Authorised

Human medicines European public assessment report (EPAR): Nordimet, methotrexate, Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Tevagrastim, filgrastim, Revision: 10, Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Revision: 33, Authorised

Human medicines European public assessment report (EPAR): Protaphane, insulin human (rDNA), Revision: 16, Authorised

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Revision: 7, Authorised

Human medicines European public assessment report (EPAR): Rasilez, aliskiren, Revision: 23, Authorised

Human medicines European public assessment report (EPAR): PritorPlus, telmisartan / hydrochlorothiazide, Revision: 32, Authorised

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Revision: 28, Authorised

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2018

PRAC held public hearing on quinolone and fluoroquinolone antibiotics

Human medicines European public assessment report (EPAR): Votubia, everolimus, Revision: 22, Authorised

Human medicines European public assessment report (EPAR): Episalvan, birch bark extract, Revision: 23, Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Revision: 26, Authorised

Human medicines European public assessment report (EPAR): Pemetrexed Hospira UK Limited, pemetrexed, Revision: 2, Authorised

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Revision: 6, Authorised

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Revision: 27, Authorised

Thursday 14th June 2018

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Revision: 1, Authorised

Human medicines European public assessment report (EPAR): Bortezomib Accord, bortezomib, Revision: 3, Authorised

News and press releases: IT systems unavailable from 15 to 18 June 2018

EMA website and online applications will be temporarily unavailable

Wednesday 13th June 2018

Human medicines European public assessment report (EPAR): Plenadren, hydrocortisone, Revision: 10, Authorised

Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine / valsartan / hydrochlorothiazide, Revision: 11, Authorised

Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Revision: 12, Authorised

Human medicines European public assessment report (EPAR): Pregabalin Zentiva k.s., pregabalin, Revision: 3, Authorised

Human medicines European public assessment report (EPAR): Twynsta, telmisartan / amlodipine, Revision: 9, Authorised


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks